Eccentric cycling during pulmonary rehabilitation for people with cardiopulmonary disease
Eccentric Cycling Exercise During Pulmonary Rehabilitation in Patients With Cardiopulmonary Diseases
This trial will test whether adding low-energy eccentric cycling to pulmonary rehabilitation helps people with pulmonary vascular or other cardiopulmonary diseases improve strength and walking ability.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Locations | 2 sites (Barmelweid and 1 other locations) |
| Trial ID | NCT07042750 on ClinicalTrials.gov |
What this trial studies
This interventional trial compares supervised eccentric cycling added to standard pulmonary rehabilitation versus standard rehabilitation alone in patients with pulmonary vascular disease (PAH or CTEPH) and other cardiopulmonary conditions. Eccentric cycling permits high muscle loading at lower metabolic and cardiopulmonary cost, and sessions are integrated into regular, longer rehabilitation periods at Klinik Barmelweid and Universitätsspital Zürich. Outcomes include muscle strength, six-minute walk distance, peak oxygen uptake (V'O2max) and safety/tolerability. The design builds on prior trials in COPD and heart failure and a feasibility randomized trial in pulmonary vascular disease.
Who should consider this trial
Good fit: Adults 18–85 years with PAH or CTEPH or another cardiopulmonary diagnosis referred for pulmonary rehabilitation, on stable medication, without resting hypoxemia, and able to complete supervised rehab.
Not a fit: Patients with comorbidities that prevent full participation in rehabilitation, significant resting hypoxemia, unstable medications, active enrollment in other interventional trials, or language barriers are unlikely to benefit.
Why it matters
Potential benefit: If successful, eccentric cycling could increase muscle strength and exercise capacity while placing less strain on the heart and lungs.
How similar studies have performed: Previous randomized trials in COPD and chronic heart failure showed greater gains in strength, hypertrophy, six-minute walk distance and V'O2max with eccentric cycling, and a small RCT in pulmonary vascular disease showed feasibility.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with PVD, either PAH or CTEPH via right heart catheterization, according to recent guidelines \[9\] * Diagnosed with a cardiopulmonary disease as indication for a pulmonary rehabilitation * Stable medication for at least 1 month * Age 18years to 85 years * No resting hypoxemia (PaO2 \>7.3 kPa) * Medical indication to prescibe a pulmonary rehabilitation Exclusion Criteria: * Any co-morbidity that limits the patient to participate the full rehabilitation * Enrollments in other trials with active treatments * Language barriers that limits the patient to participate in the rehabilitation
Where this trial is running
Barmelweid and 1 other locations
- Klinik Barmelweid — Barmelweid, Switzerland (Recruiting)
- Universitätsspital Zürich — Zurich, Switzerland (Recruiting)
Study contacts
- Study coordinator: Silvia Ulrich, Prof. dr. med.
- Email: silvia.ulrich@usz.ch
- Phone: +41442564362
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.